東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pancreatic cancer = current therapeu...

Pant, Shubham.

FindBook

Google Book

Amazon

博客來

Pancreatic cancer = current therapeutics and future directions /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pancreatic cancer/ edited by Shubham Pant.
其他題名:	current therapeutics and future directions /
其他作者:	Pant, Shubham.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	vii, 196 p. :illustrations (some col.), digital ;24 cm.
內容註:	Resectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy -- Borderline Resectable and Locally Advanced Pancreatic Cancer -- Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms -- Therapies for Metastatic Pancreatic Cancer -- Targeted Therapies for Pancreatic Cancer -- Immunotherapy for Pancreatic Cancer -- Liquid Biopsies for pancreatic cancer: Is it ready for prime time? -- Supportive Care challenges and management in Pancreatic Cancer -- Physical activity and nutrition optimization in pancreatic cancer.
Contained By:	Springer Nature eBook
標題:	Pancreas - Cancer. -
電子資源:	https://doi.org/10.1007/978-3-031-38623-7
ISBN:	9783031386237

Pancreatic cancer = current therapeutics and future directions /
Pancreatic cancercurrent therapeutics and future directions /[electronic resource] :edited by Shubham Pant. - Cham :Springer International Publishing :2023. - vii, 196 p. :illustrations (some col.), digital ;24 cm.

Resectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy -- Borderline Resectable and Locally Advanced Pancreatic Cancer -- Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms -- Therapies for Metastatic Pancreatic Cancer -- Targeted Therapies for Pancreatic Cancer -- Immunotherapy for Pancreatic Cancer -- Liquid Biopsies for pancreatic cancer: Is it ready for prime time? -- Supportive Care challenges and management in Pancreatic Cancer -- Physical activity and nutrition optimization in pancreatic cancer.

Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a "cold", non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents. This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the "Next" in drug development including molecularly targeted therapy and efforts at "Drugging the Undruggable": the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or "liquid biopsies" will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.

ISBN: 9783031386237

Standard No.: 10.1007/978-3-031-38623-7doiSubjects--Topical Terms:

823557
Pancreas
--Cancer.

LC Class. No.: RC280.P25

Dewey Class. No.: 616.99437

Pancreatic cancer = current therapeutics and future directions /
LDR:03570nmm a2200325 a 4500 001 2336296
003 DE-He213
005 20231107185310.0
006 m d
007 cr nn 008maaau
008 240402s2023 sz s 0 eng d
020 $a 9783031386237 $q (electronic bk.)
020 $a 9783031386220 $q (paper)
024 7 $a 10.1007/978-3-031-38623-7 $2 doi
035 $a 978-3-031-38623-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.P25
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99437 $2 23
090 $a RC280.P25 $b P188 2023
245 0 0 $a Pancreatic cancer $h [electronic resource] : $b current therapeutics and future directions / $c edited by Shubham Pant.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a vii, 196 p. : $b illustrations (some col.), digital ; $c 24 cm.
505 0 $a Resectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy -- Borderline Resectable and Locally Advanced Pancreatic Cancer -- Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms -- Therapies for Metastatic Pancreatic Cancer -- Targeted Therapies for Pancreatic Cancer -- Immunotherapy for Pancreatic Cancer -- Liquid Biopsies for pancreatic cancer: Is it ready for prime time? -- Supportive Care challenges and management in Pancreatic Cancer -- Physical activity and nutrition optimization in pancreatic cancer.
520 $a Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a "cold", non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents. This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the "Next" in drug development including molecularly targeted therapy and efforts at "Drugging the Undruggable": the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or "liquid biopsies" will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.
650 0 $a Pancreas $x Cancer. $3 823557
650 0 $a Pancreas $x Cancer $x Treatment. $3 1622021
650 1 4 $a Oncology. $3 751006
650 2 4 $a Internal Medicine. $3 858559
700 1 $a Pant, Shubham. $3 3669296
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-38623-7
950 $a Medicine (SpringerNature-11650)